Leerink analysts Seamus Fernandez and Aneesh Kapur say they are "growing increasingly concerned" that the recent rally in shares of Eli Lilly is being driven by solanezumab's potential to treat Alzheimer's disease based solely on the data from the Alzheimer's Association International Conference abstract. The analysts think the rise in shares embeds significant additional value for solanezumab while the full Phase III data are still 15-18 months out. They feel no definitive conclusions can be drawn on solanezumab given the open label non-randomized nature of the EXPEDITION EXT results. Fernandez and Kapur keep an Outperform rating on Lilly shares. The stock rallied $3.42 yesterday to $86.60.